Werewolf Therapeutics, Inc. (HOWL)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
HOWL Insider Trading Activity
HOWL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Werewolf Therapeutics, Inc.
Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $0 worth of Werewolf Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $50.56M and sold $40,242 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,853,000 shares for transaction amount of $4.1M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2023‑01‑06.
List of Insider Buy and Sell Transactions, Werewolf Therapeutics, Inc.
| 2023-01-06 | RA CAPITAL MANAGEMENT, L.P. | director | 1.85M 5.9218% | $2.21 | $4.1M | +17.78% | ||
| 2021-12-15 | Sale | Leonard Reid | Chief Operating Officer | 3,000 0.0157% | $13.41 | $40,242 | -65.47% | |
| 2021-06-16 | RA CAPITAL MANAGEMENT, L.P. | 9,285 0.0512% | $13.37 | $124,140 | +0.29% | |||
| 2021-06-15 | RA CAPITAL MANAGEMENT, L.P. | 7,958 0.0452% | $12.95 | $103,056 | +6.61% | |||
| 2021-06-14 | RA CAPITAL MANAGEMENT, L.P. | 306,055 1.727% | $12.75 | $3.9M | +7.62% | |||
| 2021-05-04 | GADICKE ANSBERT | 10 percent owner | 245,000 1.3777% | $16.00 | $3.92M | -12.48% | ||
| 2021-05-04 | EVNIN LUKE | 150,799 0.848% | $16.00 | $2.41M | -12.48% | |||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. | 1.72M 9.6439% | $16.00 | $27.44M | -12.48% | |||
| 2021-05-04 | MPM BioVentures 2014, L.P. | 10 percent owner | 125,759 0.7072% | $16.00 | $2.01M | -12.48% | ||
| 2021-05-04 | Flynn James E | 10 percent owner | 800,000 4.4986% | $16.00 | $12.8M | -12.48% | ||
| 2021-05-04 | Taiho Ventures LLC | 10 percent owner | 312,500 1.7573% | $16.00 | $5M | -12.48% | ||
| 2021-05-04 | Asanuma Sakae | 312,500 1.7573% | $16.00 | $5M | -12.48% | |||
| 2021-05-04 | Lazarus Alon | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | |||
| 2021-05-04 | Arkin Bio Ventures 2 L.P. | 10 percent owner | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | ||
| 2021-05-04 | Longwood Fund III GP, LLC | 10 percent owner | 250,000 1.4058% | $16.00 | $4M | -12.48% | ||
| 2021-05-04 | Sphera Global Healthcare Management LP | 10 percent owner | 475,000 2.671% | $16.00 | $7.6M | -12.48% | ||
| 2020-12-23 | EVNIN LUKE | 15.88M – | $0 | $0 | +1097.36% | |||
| 2020-12-23 | Asanuma Sakae | 7.6M – | $0.46 | $3.5M | +1097.36% | |||
| 2020-12-23 | Lazarus Alon | 7.12M – | $8.00 | $56.97M | +1097.36% |
Insider Historical Profitability
| GADICKE ANSBERT | 10 percent owner | 6672183 14.8842% | $7.14M | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | director | 5701056 12.7178% | $6.1M | 5 | 0 | +3.97% |
| EVNIN LUKE | 4284172 9.5571% | $4.58M | 2 | 0 | <0.0001% | |
| MPM BioVentures 2014, L.P. | 10 percent owner | 3187998 7.1117% | $3.41M | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 2552787 5.6947% | $2.73M | 1 | 0 | <0.0001% |
| Asanuma Sakae | 2068909 4.6153% | $2.21M | 2 | 0 | <0.0001% | |
| Taiho Ventures LLC | 10 percent owner | 2068909 4.6153% | $2.21M | 1 | 0 | <0.0001% |
| Lazarus Alon | 2046634 4.5656% | $2.19M | 2 | 0 | <0.0001% | |
| Arkin Bio Ventures 2 L.P. | 10 percent owner | 2046634 4.5656% | $2.19M | 1 | 0 | <0.0001% |
| Longwood Fund III GP, LLC | 10 percent owner | 1677082 3.7412% | $1.79M | 1 | 0 | <0.0001% |
| Sphera Global Healthcare Management LP | 10 percent owner | 787997 1.7579% | $843,156.79 | 1 | 0 | <0.0001% |
| Leonard Reid | Chief Operating Officer | 122157 0.2725% | $130,707.99 | 0 | 1 |
Historical Insider Profitability vs. Competitors
$4,273,853 | 101 | -36.67% | $48.23M | |
$15,956,086 | 53 | 5.33% | $47.76M | |
$77,062,892 | 41 | 13.96% | $44.8M | |
$459,011,221 | 33 | 33.04% | $46.39M | |
$1,087,418 | 21 | 1.95% | $47.04M | |
$160,539,875 | 21 | -6.57% | $45.49M | |
$47,863,113 | 17 | -22.07% | $50.3M | |
Werewolf Therapeutics, Inc. (HOWL) | $91,209,456 | 15 | -7.00% | $47.97M |
$13,512,915 | 12 | 73.94% | $45.67M | |
$478,647 | 7 | 69.41% | $50.57M | |
$22,090,972 | 7 | -3.49% | $46.89M | |
$17,872,846 | 6 | -27.97% | $53.54M | |
$119,593,679 | 6 | -21.91% | $54.42M | |
$15,652,720 | 6 | -4.77% | $49.39M | |
$43,326,461 | 6 | 16.01% | $52.63M | |
$762,555 | 4 | -34.52% | $48.46M | |
$157,740 | 3 | 153.95% | $50.77M | |
$32,000,000 | 3 | -41.00% | $47.19M | |
$29,875 | 1 | -22.06% | $46.24M |
HOWL Institutional Investors: Active Positions
| Increased Positions | 40 | +66.67% | 550,969 | +1.71% |
| Decreased Positions | 21 | -35% | 5M | -14.25% |
| New Positions | 11 | New | 146,564 | New |
| Sold Out Positions | 8 | Sold Out | 3M | Sold Out |
| Total Postitions | 79 | +31.67% | 28M | -12.54% |
HOWL Ownership Change vs Market
Institutional Investor Ownership
| Ra Capital Management, L.P. | $6,944.00 | 13.66% | 6.14M | 0 | 0% | 2024-12-31 |
| Mpm Asset Management Llc | $4,841.00 | 9.52% | 4.28M | 0 | 0% | 2024-12-31 |
| Pfm Health Sciences, Lp | $3,283.00 | 6.46% | 2.91M | -493,282 | -14.51% | 2024-12-31 |
| Mpm Bioimpact Llc | $2,698.00 | 5.31% | 2.39M | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $2,349.00 | 4.62% | 2.08M | -74,842 | -3.48% | 2024-12-31 |
| Blackrock, Inc. | $1,921.00 | 3.78% | 1.7M | +63,382 | +3.87% | 2024-12-31 |
| Vanguard Group Inc | $1,606.00 | 3.16% | 1.42M | +5,439 | +0.38% | 2024-12-31 |
| Rubric Capital Management Lp | $1,507.00 | 2.96% | 1.33M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $794.00 | 1.56% | 702,558 | +16,569 | +2.42% | 2024-12-31 |
| Sphera Funds Management Ltd. | $708.00 | 1.39% | 626,810 | 0 | 0% | 2024-12-31 |